Drug Trial Radar · NCT00108017
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
Last checked: Nov 20, 2026Latest source record: May 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Apr 2005
Primary completion
Jul 2006
Study completion Jul 2006
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
MK0507A, dorzolamide hydrochloride (+) timolol maleateDrug
Comparator: timolol maleateDrug
Duration of Treatment: Part 1) 6 wk timolol maleate run inDrug
Part 2) 6 wk washout pd Part 3) two 8 wk active tx pdsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24 hour diurnal IOP reduction after 8 weeks of treatmentTime frame: After 8 weeks of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.